Keyphrases
Eosinophilic Esophagitis
100%
Population-based
60%
Diagnostic Delay
50%
Celiac Trunk
50%
Population-based Study
50%
Real-world Experience
50%
Treatment Efficacy
50%
Budesonide Orodispersible Tablet
50%
Histological Remission
43%
Food Bolus Obstruction
38%
Denmark
35%
Vascular Tension
25%
Splenic Infarction
25%
Splenic Artery
25%
Treatment Response
20%
Histologic Evaluation
16%
Non-responders
16%
Remission
16%
Retrospective Longitudinal Study
10%
Medical Treatment
10%
Working Diagnosis
10%
Adult Patients
10%
Diagnostic Endoscopy
10%
Well-defined
10%
Register-based Cohort
10%
Population-based Cohort
10%
Symptomatic Remission
10%
In(III)
8%
Immune-mediated Diseases
8%
Eosinophils
8%
High-power Field
8%
Second-line Treatment
8%
Biological Agents
8%
Proton Pump Inhibitors
8%
Population-based Setting
8%
Medical Records
8%
Registry-based
8%
Symptom Response
8%
Stricture
8%
Treatment Options
8%
Medical Reports
8%
Esophagitis
8%
Medicine and Dentistry
Eosinophilic Esophagitis
100%
Diagnostic Delay
50%
Methylphenidate
50%
Celiac Artery
50%
Budesonide
50%
Personal Experience
50%
Obstruction
38%
Splenic Infarction
25%
Treatment Response
20%
Side Effect
16%
Endoscopy
10%
Diagnosis
10%
Cross Sectional Study
10%
Symptom
10%
Patient with Complication
10%
Combination Therapy
10%
Eosinophil
8%
Stricture
8%
Diseases
8%
Biological Product
8%
Immunity
8%
Proton-Pump Inhibitor
8%
Medical Record
8%
Cohort Analysis
8%
Esophagitis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Budesonide
50%
Tablet
50%
Eosinophilic Esophagitis
50%
Remission
50%
Spleen Infarction
25%
Side Effect
16%
Cohort Study
8%
Proton Pump Inhibitor
8%
Disease
8%
Biological Product
8%
Obstruction
8%
Esophagitis
8%
